Sign In
Buy ROG
$148.00
-6.22 (-4.03%)
At Close: Jun 03, 2026
Dupont ends $5.2 billion deal to buy Rogers Corp.
05:27pm, Tuesday, 01'st Nov 2022
DuPont de Nemours Inc. DD, +2.62% said late Tuesday it has ended its deal to buy Arizona-based engineered-materials maker Rogers Corp. as the companies could not get "timely clearance" from all the re
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
03:45pm, Wednesday, 26'th Oct 2022 GlobeNewswire Inc.
Basel, 26 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) data on disease progression and healthcare costs in patients with early-stage RRMS and long-term
Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems
05:00am, Monday, 24'th Oct 2022 GlobeNewswire Inc.
Basel, 24 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the cobas® SARS-CoV-2 Qualitative PCR tes
Ready to Buy the Dip? This Healthcare Stock Is a Smart Buy
10:30am, Wednesday, 19'th Oct 2022 The Motley Fool
DexCom's latest products could drive lasting growth.
Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
05:00am, Wednesday, 19'th Oct 2022 GlobeNewswire Inc.
Basel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) will be pre
[Annonce événementielle selon l’art. 53 RC] Roche affiche de solides résultats pour les neuf premiers mois de 2022
05:00am, Tuesday, 18'th Oct 2022 GlobeNewswire Inc.
Bâle, le 18 octobre 2022
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit soliden Ergebnissen in den ersten neun Monaten 2022
05:00am, Tuesday, 18'th Oct 2022 GlobeNewswire Inc.
Basel, 18. Oktober 2022
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
05:00am, Tuesday, 18'th Oct 2022 GlobeNewswire Inc.
Basel, 18 October 2022
Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use
05:03am, Wednesday, 12'th Oct 2022 GlobeNewswire Inc.
Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for self-testing and professional use
Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
05:00am, Wednesday, 12'th Oct 2022 GlobeNewswire Inc.
Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months t
Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma
05:00am, Tuesday, 11'th Oct 2022 GlobeNewswire Inc.
Basel, 11 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue sampl
Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
05:00am, Wednesday, 05'th Oct 2022 GlobeNewswire Inc.
Basel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading neuromuscular portfolio will be presented at the World Muscle Society (WMS) congress
Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU
05:00am, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
Basel, 4 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* t
[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023
05:00am, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Basel, 3 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Matt Sause (45), currently Head of Roche Diagnostics’ North America Region, will become CEO Roche Diagnostics and a me
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche: Wechsel in der Konzernleitung im Januar 2023
05:00am, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Basel, 3. Oktober 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass Matt Sause (45), derzeit Leiter der Region Nordamerika von Roche Diagnostics, ab dem 1. Januar 2023 CEO von Roche
